SG59692G - Salts of amlodipine - Google Patents

Salts of amlodipine

Info

Publication number
SG59692G
SG59692G SG596/92A SG59692A SG59692G SG 59692 G SG59692 G SG 59692G SG 596/92 A SG596/92 A SG 596/92A SG 59692 A SG59692 A SG 59692A SG 59692 G SG59692 G SG 59692G
Authority
SG
Singapore
Prior art keywords
amlodipine
salts
Prior art date
Application number
SG596/92A
Other languages
English (en)
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG59692(G) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of SG59692G publication Critical patent/SG59692G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
SG596/92A 1986-04-04 1992-06-04 Salts of amlodipine SG59692G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608335A GB8608335D0 (en) 1986-04-04 1986-04-04 Pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
SG59692G true SG59692G (en) 1992-12-04

Family

ID=10595731

Family Applications (1)

Application Number Title Priority Date Filing Date
SG596/92A SG59692G (en) 1986-04-04 1992-06-04 Salts of amlodipine

Country Status (47)

Country Link
US (1) US4879303A (fi)
EP (1) EP0244944B1 (fi)
JP (1) JPS62240660A (fi)
KR (1) KR950006710B1 (fi)
CN (1) CN1023800C (fi)
AP (1) AP50A (fi)
AR (1) AR242562A1 (fi)
AT (1) ATE49752T1 (fi)
BE (1) BE1000130A4 (fi)
BG (1) BG60698B2 (fi)
CA (1) CA1321393C (fi)
CS (1) CS265237B2 (fi)
CY (1) CY1669A (fi)
CZ (1) CZ289095B6 (fi)
DD (1) DD265142A5 (fi)
DE (2) DE3710457A1 (fi)
DK (1) DK171708B1 (fi)
EC (1) ECSP941129A (fi)
EG (1) EG18266A (fi)
ES (2) ES2012803B3 (fi)
FI (1) FI85017C (fi)
FR (1) FR2596758B1 (fi)
GB (2) GB8608335D0 (fi)
GR (2) GR870525B (fi)
HK (1) HK76092A (fi)
HU (1) HU196962B (fi)
IE (1) IE59457B1 (fi)
IL (1) IL82101A (fi)
IN (1) IN168414B (fi)
IT (1) IT1203853B (fi)
LU (1) LU86812A1 (fi)
MA (1) MA20938A1 (fi)
MX (1) MX5847A (fi)
MY (1) MY101177A (fi)
NL (1) NL8700791A (fi)
NO (1) NO172181C (fi)
NZ (1) NZ219868A (fi)
PH (1) PH24348A (fi)
PL (1) PL149532B1 (fi)
PT (1) PT84611B (fi)
SE (1) SE463457B (fi)
SG (1) SG59692G (fi)
SK (1) SK278435B6 (fi)
SU (1) SU1498388A3 (fi)
UA (1) UA6344A1 (fi)
YU (1) YU44801B (fi)
ZA (1) ZA872439B (fi)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
CA2124445A1 (en) * 1991-11-26 1993-06-10 James W. Young Methods and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AT399718B (de) * 1992-04-16 1995-07-25 Lek Tovarna Farmacevtskih Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
SI9200344B (sl) * 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
US5389654A (en) * 1992-11-26 1995-02-14 Lek, Tovarna, Farmacevtskih In Kemicnih . . . 3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JPH11500140A (ja) 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
HU221810B1 (hu) * 1997-08-12 2003-01-28 EGIS Gyógyszergyár Rt. Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU6767198A (en) * 1998-03-26 1999-05-03 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition containing amlodipine besylate and atenol ol
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
PT1096932E (pt) 1998-07-10 2007-09-21 Novartis Pharma Ag ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio''
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7129265B2 (en) * 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
JP2003500487A (ja) 1999-05-27 2003-01-07 ファイザー・プロダクツ・インク アムロジピンおよびアトルバスタチンの共通プロドラッグ
UA72768C2 (en) 1999-07-05 2005-04-15 Richter Gedeon Vegyeszet A method for obtaining amilodipine benzenesulphonate
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2002011723A1 (en) 2000-08-04 2002-02-14 Mason R Preston Synergistic effect of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
WO2002053542A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Process for making amlodipine maleate
BR0116552A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
MXPA03005886A (es) * 2000-12-29 2005-04-19 Pfizer Ltd Derivado de aspartato de amlodipina como antagonista del canal de calcio.
WO2002053538A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine fumarate
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
ATE356806T1 (de) * 2001-01-09 2007-04-15 Siegfried Generics Int Ag Salze von amlodipin-mesylat
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
US20030027848A1 (en) * 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
EP1435954B1 (en) * 2001-07-06 2010-01-13 LEK Pharmaceuticals D.D. A PROCESS FOR THE PREPARATION OF HIGHlLY PUREAMLODIPINE BENZENESULFONATE
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040001886A1 (en) * 2001-10-17 2004-01-01 Dr. Reddy's Laboratories Limited Stabilized pharmaceutical formulations containing amlodipine maleate
US6828339B2 (en) * 2001-11-21 2004-12-07 Synthon Bv Amlodipine salt forms and processes for preparing them
HU226642B1 (en) * 2001-12-17 2009-05-28 Egis Gyogyszergyar Nyilvanosan Amlodipine bezylate tablets having extended stability and process for producing the same
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP1499592A4 (en) * 2002-04-13 2010-01-13 Hanlim Pharmaceutical Co Ltd AMLODIPINE NICOTINATE AND PROCESS FOR PREPARING THE SAME
KR100978418B1 (ko) 2002-05-06 2010-08-26 엔도사이트, 인코포레이티드 비타민-표적된 영상제
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SI21233A (sl) * 2002-05-31 2003-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Kristalni hidratni obliki amlodipin benzensulfonata visoke čistote, postopki za njuno pripravo in uporaba
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
KR100496436B1 (ko) 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100538641B1 (ko) 2002-07-30 2005-12-22 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR20040011751A (ko) * 2002-07-30 2004-02-11 씨제이 주식회사 암로디핀의 유기산염
KR100467669B1 (ko) 2002-08-21 2005-01-24 씨제이 주식회사 암로디핀의 유기산염
JP3746063B2 (ja) 2002-08-29 2006-02-15 大正製薬株式会社 ４−フルオロ−２−シアノピロリジン誘導体ベンゼンスルホン酸塩
US6784297B2 (en) * 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
AU2003260984A1 (en) 2002-09-11 2004-04-30 Hanlim Pharmaceutical Co., Ltd. S-(-)-amlodipine nicotinate and process for the preparation thereof
AU2003253460A1 (en) * 2002-09-19 2004-04-08 Cj Corporation Crystalline organic acid salt of amlodipine
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
EP1407773A1 (en) * 2002-10-08 2004-04-14 Council of Scientific and Industrial Research A process for the preparation of s (-) amlodipine salts
US20040072879A1 (en) * 2002-10-10 2004-04-15 Dr. Reddy's Laboratories Limited Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
WO2004058711A1 (en) * 2002-12-30 2004-07-15 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Isolation of dihydropyridine derivative and preparation salts thereof
US20060128763A1 (en) 2003-01-27 2006-06-15 Moon Young H Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
KR20040072363A (ko) * 2003-02-12 2004-08-18 주식회사 대웅 신규한 암로디핀 사이클라메이트 염 및 그의 제조방법
US20060270715A1 (en) * 2003-02-28 2006-11-30 Singh Romi B Dosage forms of amlodipine and processes for their preparation
DK1618111T3 (en) 2003-04-25 2015-02-16 Cadila Healthcare Ltd Salts of clopidogrel and the process for preparing
WO2004096770A1 (en) * 2003-04-25 2004-11-11 Cipla Limited Process for preparing almodipine mesylate monohydrate
AU2004247627A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
EA009646B1 (ru) 2003-05-30 2008-02-28 Рэнбакси Лабораториз Лтд. Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
KR100841409B1 (ko) * 2003-12-16 2008-06-25 에스케이케미칼주식회사 암로디핀 겐티세이트 염과 이의 제조방법
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030602A1 (en) * 2004-03-16 2006-02-09 Sepracor Inc. (S)-amlodipine malate
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006026555A2 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
JP2008516977A (ja) * 2004-10-15 2008-05-22 セオ ホン ユー 薬剤学的化合物の毒性を減少させるための方法及び組成物
ATE491456T1 (de) * 2004-11-01 2011-01-15 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
WO2006059217A1 (en) * 2004-12-01 2006-06-08 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine besylate and processes for their preparation
WO2006070248A1 (en) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
WO2006085208A2 (en) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Stable solid dosage forms of amlodipine and benazepril
EP1888120B1 (en) * 2005-06-07 2012-12-05 Ramot at Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
KR20130135994A (ko) * 2005-06-27 2013-12-11 다이이찌 산쿄 가부시키가이샤 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1932528A1 (en) * 2005-09-28 2008-06-18 Teva Pharmaceutical Industries Ltd Stable composition of amlodipine besylate
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
US8222296B2 (en) 2006-07-17 2012-07-17 Ramot At Tel-Aviv University Ltd. Conjugates comprising a GABA- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating CNS disorders
KR100795313B1 (ko) 2006-09-05 2008-01-21 현대약품 주식회사 암로디핀 베실레이트를 포함하는 약학 조성물
TWI399223B (zh) 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2008076458A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
CN101652131A (zh) 2007-01-29 2010-02-17 韩兀制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
US8143314B1 (en) * 2007-09-13 2012-03-27 Robert Carl Stover Methods and formulations for treating ineffective or decreased esophageal motility
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
MX2010007281A (es) 2007-12-31 2010-10-05 Lupin Ltd Composiciones farmaceuticas de amlodipina y valsartan.
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
CN101564536B (zh) * 2008-04-21 2010-12-15 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物缓控释制剂
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
MX360970B (es) 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
JPWO2010070705A1 (ja) * 2008-12-17 2012-05-24 株式会社 メドレックス アムロジピンの安定な含水経口製剤
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
ES2565644T3 (es) * 2009-11-09 2016-04-06 Xenoport, Inc. Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
CA2782514A1 (en) 2009-12-09 2011-06-16 Biolinerx Ltd. Methods of improving cognitive functions
HUE030969T2 (en) 2010-02-12 2017-06-28 Pfizer Salts and Polymorphs of 8-Fluoro-2- {4 - [(methylamino) methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-CD] indol-6-one
JP2013520488A (ja) 2010-02-24 2013-06-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
WO2011117876A1 (en) 2010-03-26 2011-09-29 Fdc Limited An improved process for the preparation of amlodipine free base and acid addition salts thereof
IT1400309B1 (it) * 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
EP2603081B1 (en) * 2010-08-10 2016-10-05 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
WO2012071524A1 (en) * 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
WO2013063401A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
CN104302178B (zh) 2012-03-15 2018-07-13 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
PL2825042T3 (pl) 2012-03-15 2019-02-28 Celgene Car Llc Sole inhibitora kinazy receptora czynnika wzrostu naskórka
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014122585A1 (en) 2013-02-08 2014-08-14 Wockhardt Limited A stable pharmaceutical composition of amlodipine and benazepril or salts thereof
KR20150119012A (ko) 2013-02-08 2015-10-23 셀진 아빌로믹스 리서치, 인코포레이티드 Erk 억제제 및 이의 용도
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN104529877A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-癸酸离子液体及其制备方法和用途
CN104523588A (zh) * 2015-01-22 2015-04-22 华东理工常熟研究院有限公司 氨氯地平-硬脂酸离子液体及其制备方法和用途
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
EP3334466B1 (en) 2015-08-14 2020-05-13 Endocyte, Inc. Method of imaging with a chelating compound
US20180303811A1 (en) 2015-10-23 2018-10-25 Ftf Pharma Private Limited Oral solution of dihydropyridine derivatives
CN105395495A (zh) * 2015-11-30 2016-03-16 宜昌东阳光长江药业股份有限公司 一种含有苯磺酸氨氯地平的组合物及其制备方法
EP3219309A1 (en) 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
JP6411662B2 (ja) 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
EP3960158A1 (en) 2016-10-07 2022-03-02 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
EP3501502A1 (en) 2017-12-20 2019-06-26 Midas Pharma GmbH Fixed dosed pharmaceutical compositions comprising amlodipine, ramipril and atorvastatin
US10799453B2 (en) 2018-04-11 2020-10-13 Silvergate Pharmaceuticals, Inc. Amlodipine formulations
US11417416B2 (en) 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
CN113574055B (zh) 2019-01-18 2024-07-23 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
US11253474B1 (en) 2021-02-01 2022-02-22 Liqmeds Worldwide Limited Pharmaceutical solution of amlodipine
EP4052695A1 (en) 2021-03-05 2022-09-07 Midas Pharma GmbH Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
EP4370101A1 (en) 2021-07-15 2024-05-22 Adamed Pharma S.A. A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816612A (en) * 1967-03-23 1974-06-11 Degussa Process for the production of basically reacting pharmaceuticals
US4032637A (en) * 1972-09-26 1977-06-28 Sandoz Ltd. Method of promoting sleep
US4177278A (en) * 1977-04-05 1979-12-04 Bayer Aktiengesellschaft 2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
CS228917B2 (en) * 1981-03-14 1984-05-14 Pfizer Method of preparing substituted derivatives of 1,4-dihydropyridine
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds

Also Published As

Publication number Publication date
DE3761485D1 (de) 1990-03-01
EP0244944A2 (en) 1987-11-11
ZA872439B (en) 1988-11-30
BG60698B2 (en) 1995-12-29
PT84611B (pt) 1989-11-30
NZ219868A (en) 1989-02-24
FI85017C (fi) 1992-02-25
GR3000394T3 (en) 1991-06-07
IE59457B1 (en) 1994-02-23
DK170187D0 (da) 1987-04-03
SU1498388A3 (ru) 1989-07-30
NO172181C (no) 1993-06-16
GB8608335D0 (en) 1986-05-08
JPH037668B2 (fi) 1991-02-04
MA20938A1 (fr) 1987-12-31
FR2596758B1 (fr) 1988-12-02
CS236387A2 (en) 1989-01-12
EG18266A (en) 1992-12-30
SK278435B6 (en) 1997-05-07
SE463457B (sv) 1990-11-26
IT1203853B (it) 1989-02-23
PH24348A (en) 1990-06-13
DK171708B1 (da) 1997-04-01
PL149532B1 (en) 1990-02-28
MY101177A (en) 1991-07-31
IL82101A0 (en) 1987-10-30
FR2596758A1 (fr) 1987-10-09
EP0244944A3 (en) 1988-01-07
IT8719977A0 (it) 1987-04-03
CN87102493A (zh) 1987-10-14
NO871408D0 (no) 1987-04-03
CZ289095B6 (cs) 2001-10-17
IE870869L (en) 1987-10-04
AR242562A1 (es) 1993-04-30
SE8701348D0 (sv) 1987-03-31
ES2002599A6 (es) 1988-08-16
FI871470A (fi) 1987-10-05
PT84611A (en) 1987-05-01
DK170187A (da) 1987-10-05
CS353991A3 (en) 1992-04-15
FI871470A0 (fi) 1987-04-03
MX5847A (es) 1993-08-01
SE8701348L (sv) 1987-10-05
EP0244944B1 (en) 1990-01-24
GB8707653D0 (en) 1987-05-07
DD265142A5 (de) 1989-02-22
HK76092A (en) 1992-10-09
NL8700791A (nl) 1987-11-02
NO172181B (no) 1993-03-08
US4879303A (en) 1989-11-07
PL264982A1 (en) 1988-05-26
CY1669A (en) 1993-05-14
KR950006710B1 (ko) 1995-06-21
ECSP941129A (es) 1994-12-15
GB2188630B (en) 1990-04-04
YU58087A (en) 1988-08-31
IL82101A (en) 1991-01-31
HU196962B (en) 1989-02-28
BE1000130A4 (fr) 1988-04-12
ATE49752T1 (de) 1990-02-15
AP50A (en) 1989-09-16
CN1023800C (zh) 1994-02-16
ES2012803B3 (es) 1990-04-16
UA6344A1 (uk) 1994-12-29
AU7103087A (en) 1987-10-08
CA1321393C (en) 1993-08-17
AP8700060A0 (en) 1987-02-01
DE3710457A1 (de) 1987-10-08
AU573123B2 (en) 1988-05-26
FI85017B (fi) 1991-11-15
LU86812A1 (fr) 1987-08-12
GB2188630A (en) 1987-10-07
CS265237B2 (en) 1989-10-13
KR870009998A (ko) 1987-11-30
GR870525B (en) 1987-08-12
NO871408L (no) 1987-10-05
YU44801B (en) 1991-02-28
HUT43821A (en) 1987-12-28
JPS62240660A (ja) 1987-10-21
IN168414B (fi) 1991-03-30

Similar Documents

Publication Publication Date Title
AR242562A1 (es) Un procedimiento para preparar la sal besilato de amlodipina.
ZA87467B (en) Isoquinoline derivatives
EP0232224A3 (en) Piperidine compounds
ZA874587B (en) Dihydropyridines
GB8527698D0 (en) Dihydropyridine antiischaemic & antihypertensive agents
GB8727401D0 (en) Preparation of trifluoromethylbenzonitrile
PH22683A (en) Dihydropyridine derivatives
ZA863578B (en) Dihydropyridine derivatives
IL82217A0 (en) Preparation of 1-aryl-5-amino-pyrazoles
GB2195636B (en) Isoquinoline derivatives
GB2196961B (en) Preparation of polyfluoroenolates
GB8714646D0 (en) Plaster
GB2194532B (en) Isoquinoline derivatives
GB8614475D0 (en) Piperidine compounds
ZA875592B (en) Isoquinoline derivatives
ZA873637B (en) Isoquinoline derivatives
IL84609A0 (en) Isoquinoline derivatives
IL82018A0 (en) Preparation of 4-nitrophenetol
IE852063L (en) Cycliciminium salts
IE860268L (en) Dihydropyridine derivatives
IE851483L (en) Dihydropyridine derivatives
GB8508736D0 (en) Dihydropyridines
GB8511350D0 (en) Dihydropyridines
CS443186A1 (en) Connection of six-outlet reflecto-meter
CS443086A1 (en) Connection of six-outlet reflecto-meter